

Down Syndrome Market Report 2032: Epidemiology Insights, Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight

DelveInsight's Down Syndrome Market report offers an in-depth understanding of the epidemiology and market trends in the 7MM.

NEVADA, LA, UNITED STATES, June 20, 2024 /EINPresswire.com/ --

DelveInsight's "Down Syndrome Market Insights, Epidemiology, and Market Forecast-2032" report offers an in-depth understanding of the Down Syndrome, historical and forecasted epidemiology as well as the Down Syndrome market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.



Down Syndrome Market

To Know in detail about the Down Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; [Down Syndrome Market Forecast](#)

Some of the key facts of the Down Syndrome Market Report:

As per DelveInsight, the Down Syndrome Market is expected to expand at a healthy growth rate during the forecast period (2023-2032), owing to the launch of new therapies in the market and the rise in the number of cases.

Key Down Syndrome Companies: AC Immune, Annovis Bio, Alzheon, OPKO Health, Inc., Aelis Farma, Eisai Inc., Elixirgen Therapeutics, Aphios Therapeutics, Avanti Biosciences, AelisFarma, Kinopharma, NeuroNascent, Inc., Pharmasum Therapeutics, and others

Key Down Syndrome Therapies: ACI-24, AEF0217, and others

According to the DSAGSL organization, approximately 400,000 Americans were diagnosed with Down syndrome in 2022, with around 6,000 babies born with the condition annually in the US. As stated by the Minnesota Health Department in 2023, Down syndrome occurs in approximately 1 out of 800 to 1,000 live births in the US and stands as the most prevalent genetic cause of developmental delay. It further delineated three types of Down syndrome: trisomy 21 (nondisjunction), which comprises 95% of cases, translocation, making up about 4%,

and mosaicism, accounting for roughly 1%.

Graaf et al. (2016) reported that in 2015, there were 419,000 individuals with Down syndrome residing in Europe. Additionally, between 2011 and 2015, there were 8,031 annual live births of children with Down syndrome, with a live birth prevalence of 10.1 per 10,000 live births.

According to Graaf et al. (2016), the estimated population prevalence of Down syndrome in the US is 1 in 1,499, encompassing approximately 206,366 individuals with the condition.

Antonarakis (2020) highlighted a significant increase in the lifetime prevalence of Down syndrome due to the global population growth. For instance, in the US, the population prevalence of Down syndrome surged from approximately 50,000 in 1950 (3.3 per 10,000 individuals) to around 212,000 in 2013 (6.7 per 10,000 individuals).

The Down Syndrome market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Down Syndrome pipeline products will significantly revolutionize the Down Syndrome market dynamics.

Down Syndrome Overview

Down syndrome, medically known as trisomy 21, is a genetic condition characterized by the presence of an extra chromosome 21, which results from abnormal cell division. This additional genetic material significantly impacts the development and cognition of affected individuals, leading to a spectrum of mental and physical challenges that require specialized care and support. Understanding the diverse manifestations of Down syndrome is crucial for promoting optimal quality of life and fostering opportunities for personal growth.

Key features of Down syndrome include distinctive facial characteristics, developmental delays, and intellectual disability. Individuals with Down syndrome are also more prone to conditions such as heart defects and thyroid disorders. Physical attributes commonly associated with the condition include a flattened facial profile, shorter neck, small ears, hands, and feet, decreased muscle tone or joint flexibility, and shorter stature during childhood and adulthood. Despite the prevalence of mild to moderate intellectual disability among individuals with Down syndrome, each person possesses unique abilities, learning styles, and developmental potentials that warrant recognition and support. Tailoring care to these individual differences is essential for providing effective personalized care.

Maternal age plays a significant role in the likelihood of having a child with Down syndrome, particularly for women aged 35 and older, who face increased risks compared to younger mothers. Interestingly, despite this higher risk profile, the majority of babies born with Down syndrome are born to mothers under 35, reflecting broader birth rate trends in this age group. This underscores the complex relationship between maternal age and the occurrence of Down syndrome, highlighting the importance of personalized care and genetic counseling for expectant mothers of all ages.

Down Syndrome Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted

epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Down Syndrome Epidemiology Segmentation:

The Down Syndrome market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

Total Prevalence of Down Syndrome

Prevalent Cases of Down Syndrome by severity

Gender-specific Prevalence of Down Syndrome

Diagnosed Cases of Episodic and Chronic Down Syndrome

Download the report to understand which factors are driving Down Syndrome epidemiology trends @ [Down Syndrome Epidemiology Forecast](#)

Down Syndrome Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Down Syndrome market or expected to get launched during the study period. The analysis covers Down Syndrome market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Down Syndrome Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Down Syndrome Therapies

ACI-24

AEF0217

Down Syndrome Key Companies

AC Immune

Annovis Bio

Alzheon

OPKO Health

Aelis Farma

Eisai Inc

Elixirgen Therapeutics

Aphios Therapeutics

Avanti Biosciences

AelisFarma
Kinopharma
NeuroNascent
Pharmasum Therapeutics

Discover more about therapies set to grab major Down Syndrome market share @ [Down Syndrome Treatment Landscape](#)

Scope of the Down Syndrome Market Report

Study Period: 2019–2032

Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

Key Down Syndrome Companies: AC Immune, Annovis Bio, Alzheon, OPKO Health, Inc., Aelis Farma, Eisai Inc., Elixirgen Therapeutics, Aphios Therapeutics, Avanti Biosciences, AelisFarma, Kinopharma, NeuroNascent, Inc., Pharmasum Therapeutics, and others

Key Down Syndrome Therapies: ACI-24, AEF0217, and others

Down Syndrome Therapeutic Assessment: Down Syndrome current marketed and Down Syndrome emerging therapies

Down Syndrome Market Dynamics: Down Syndrome market drivers and Down Syndrome market barriers

Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

Down Syndrome Unmet Needs, KOL's views, Analyst's views, Down Syndrome Market Access and Reimbursement

Table of Contents

1. Down Syndrome Market Report Introduction
2. Executive Summary for Down Syndrome
3. SWOT analysis of Down Syndrome
4. Down Syndrome Patient Share (%) Overview at a Glance
5. Down Syndrome Market Overview at a Glance
6. Down Syndrome Disease Background and Overview
7. Down Syndrome Epidemiology and Patient Population
8. Country-Specific Patient Population of Down Syndrome
9. Down Syndrome Current Treatment and Medical Practices
10. Down Syndrome Unmet Needs
11. Down Syndrome Emerging Therapies
12. Down Syndrome Market Outlook
13. Country-Wise Down Syndrome Market Analysis (2019–2032)
14. Down Syndrome Market Access and Reimbursement of Therapies
15. Down Syndrome Market Drivers
16. Down Syndrome Market Barriers
17. Down Syndrome Appendix

18. Down Syndrome Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Kritika Rehani

DelveInsight Business Research LLP

+1 469-945-7679

[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/721569148>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.